MiR-708-5p targets oncogenic prostaglandin E2 production in lung cancer cell

Pinterest LinkedIn Tumblr +

As reported in volume 11, Issue 26 of Oncotarget, Lung cancer is of particular importance.

It is the deadliest cancer worldwide.

In this study, the authors show that high mi R-708 expression is associated with survival rates in lung squamous cell carcinoma patients. mi R-708 also represses PGE2 production by suppressing both COX-2 and mPGES-1 expression in lung cancer cells.

Moreover, mi R-708 decreases proliferation, survival, and migration of lung cancer cells, which can be partially attributed to mi R-708’s inhibition of PGE2 signalilng.

Lastly, they identify novel mi R-708 predicted targets and possible regulators of mi R-708 expression in lung cancer.

Collectively, these data demonstrate that dysregulated mi R-708 expression contributes to exacerbated PGE2 production, leading to an enhanced pro-tumourigenic phenotype in lung cancer cells.

Dr. Carol S. Lutz from The Department of Microbiology, Biochemistry, and Molecular Genetics at Rutgers Biomedical & Health Sciences, New Jersey Medical School, School of Graduate Studies in Newark, New Jersey, USA, said, “Lung cancer is the most common cancer, with more than 2.09 million lung cancer cases worldwide in 2018.”

More importantly, lung cancer is the deadliest cancer in the world, with more than 1.79 million lung cancer-related deaths in 2018.

Lung cancer is a collection of several distinct subtypes, with non-small cell lung cancer accounting for 85% of all lung tumours. mi R-708 also indirectly regulates the expression of genes involved in PI3K signalling, cell cycle progression, epithelial-mesenchymal transition, and cancer cell stemness.

In this study, the authors aim to decipher novel mi R-708 targets and suggest a solution to the controversy on whether mi R-708 is an oncogenic or tumour-suppressive mi RNA in lung cancer.

The Lutz Research Team concluded in their Oncotarget Research Paper that collectively, their findings suggest further study of mi R-708 in lung cancer.

The data paired with previous studies highlight a potential value for mi R-708 as a diagnostic in differentiating lung tumours, as well as a potential therapeutic intervention, particularly in lung squamous cell carcinomas.

Their work has identified novel tumour-suppressive mi R-708 functions by suppressing oncogenic PGE2 production through targeting of COX-2 and mPGES-1.

These findings could be the foundation for identifying novel mi R-708 targets, as well as regulators of mi R-708 expression in cancer.

Moreover, the study highlights the need to better understand lung cancer biology to improve the diagnosis and treatment of lung cancer, ultimately aiming to increase positive patient outcomes.

Source: Impact Journals LLC


About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.